Our mission is to harness the power of our understanding of cellular membranes and porosome-mediated secretion, to mitigate pathogen entry, identify and create patent-pending high-value therapies for currently unarguable porosome protein and lipid targets and transform human health.
To achieve this objective, we have assembled a multidisciplinary team of experts, with decades of experience in the field and in the development of novel therapeutics to treat debilitating diseases and improve human lives.
To develop novel therapies focused on our ‘Membrane & Porosome Proteome & Lipidome (PPL) Technology' platform, to mitigate virus infections (SARS-CoV-2, Influenza, Hepatitis), and to treat diabetes, neurological disorder and cancer. Our mission is to provide access to all these curative therapies globally.
To achieve this, the design and development of the new generation of VIRONTM anti-viral, anti-cancer, anti-neurological and anti-diabetes drugs are initiated in the laboratory and driven by results from decades of research by experts in the field, followed by investigation of the clinical outcome in humans.